NASDAQ:NRBO - NeuroBo Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.00
  • Forecasted Upside: 354.55 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.52
▲ +0.23 (6.99%)

This chart shows the closing price for NRBO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NeuroBo Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NRBO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NRBO

Analyst Price Target is $16.00
▲ +354.55% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for NeuroBo Pharmaceuticals in the last 3 months. The average price target is $16.00, with a high forecast of $16.00 and a low forecast of $16.00. The average price target represents a 354.55% upside from the last price of $3.52.

This chart shows the closing price for NRBO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in NeuroBo Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/9/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/9/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/7/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/5/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/3/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/4/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/3/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/2/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/20/2021HC WainwrightReiterated RatingBuy$16.00High
2/1/2021HC WainwrightLower Price TargetBuy$20.00 ➝ $16.00Low
11/16/2020HC WainwrightReiterated RatingBuy$20.00High
6/15/2020HC WainwrightInitiated CoverageBuy$20.00High
2/18/2020LADENBURG THALM/SH SHInitiated CoverageBuyHigh
(Data available from 8/2/2016 forward)
NeuroBo Pharmaceuticals logo
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for coronavirus, neurodegenerative, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which has completed Phase 2 clinical trial to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $3.52
Low: $3.25
High: $3.65

50 Day Range

MA: $3.11
Low: $2.73
High: $3.97

52 Week Range

Now: $3.52
Low: $2.70
High: $7.61

Volume

815,489 shs

Average Volume

1,283,025 shs

Market Capitalization

$78.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.64

Frequently Asked Questions

What sell-side analysts currently cover shares of NeuroBo Pharmaceuticals?

The following Wall Street analysts have issued stock ratings on NeuroBo Pharmaceuticals in the last year: HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for NRBO.

What is the current price target for NeuroBo Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for NeuroBo Pharmaceuticals in the last year. Their average twelve-month price target is $16.00, suggesting a possible upside of 354.5%. HC Wainwright has the highest price target set, predicting NRBO will reach $16.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $16.00 for NeuroBo Pharmaceuticals in the next year.
View the latest price targets for NRBO.

What is the current consensus analyst rating for NeuroBo Pharmaceuticals?

NeuroBo Pharmaceuticals currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NRBO will outperform the market and that investors should add to their positions of NeuroBo Pharmaceuticals.
View the latest ratings for NRBO.

What other companies compete with NeuroBo Pharmaceuticals?

How do I contact NeuroBo Pharmaceuticals' investor relations team?

NeuroBo Pharmaceuticals' physical mailing address is 200 Berkeley Street Office 19th Floor, Boston MA, 02116. The company's listed phone number is 734-245-1700 and its investor relations email address is [email protected] The official website for NeuroBo Pharmaceuticals is www.neurobopharma.com.